BresaGen executes supply contracts
Friday, 27 January, 2006
Adelaide biotechnology manufacturer BresaGen (ASX:BGN) has executed supply contracts worth AUD$680,000 with WA based junior biotech Caldeon and Brisbane's Tissue Therapies (ASX:TIS).
Caldeon is collaborating with the University of Western Australia to optimise osteoporosis drug leads which could reduce bone loss.
BresaGen offers process development and manufacture of recombinant peptides and proteins providing an alternative to peptide manufacture using chemical synthesis. The company has a proprietary fusion protein system that allows high level expression and inclusion body formation of proteins and peptides in E. Coli.
BresaGen has now provided several Australian biotech companies with process development and supply of material for various stages of product development including, CBio, Hunter Immunology, QRx, Imugene (ASX:IMU) and Psiron (ASX:PSX).
Liquid fat treatment provides hope for rare childhood disease
A liquid fat supplement, triheptanoin, can reverse mitochondrial dysfunction and cell death in...
NSW Govt delivers foot-and-mouth vaccine to protect livestock
A biodegradable vaccine to protect livestock from foot-and-mouth disease has been developed as...
Scientists optimise delivery of mRNA to target cells
A highly versatile new method captures and attaches antibodies to the surface of mRNA-loaded...
